在委内瑞拉消除瘤病的得分卡方法
Oneida Camacho1, Carlos Botto1, Dalila Ríos2
1Centro Amazónico de Investigación y Control de Enfermedades Tropicales "Simón Bolívar" (SACAICET), Ministerio del Poder Popular para la Salud, Puerto Ayacucho, Venezuela.
The American journal of tropical medicine and hygiene
|June 11, 2024
概括
评分卡方法 (SCA) 优先考虑委内瑞拉瘤瘤治疗的社区,提高计划的效率. 这一数据驱动的战略有助于在2025年之前在美国的最后一个重点地区消除这种疾病.
科学领域:
- 公共卫生 公共卫生
- 热带医学 热带医学
- 流行病学 流行病学
背景情况:
- 在亚马逊,特别是横跨巴西和委内瑞拉的亚诺玛米焦点地区,瘤瘤仍然是特有病.
- 大量服用ivermectin的药物成功消除了美洲13个焦点中的11个焦点上的瘤.
- 剩余的传播区面临着独特的挑战,包括偏远和人口流动性.
研究的目的:
- 描述评分卡方法 (SCA) 的开发和实施,这是一个数据驱动的工具,用于优先考虑胆固醇控制工作.
- 提高委内瑞拉南方重点计划的节目效率和规划.
- 支持到2025年在美洲中断球病传播的目标.
主要方法:
- 评分卡方法 (SCA) 开发用于根据流行病学和后勤变量分配数字分数.
- 根据综合分数,社区被分为高,中,低优先级.
- 自2018年以来,SCA每年向委内瑞拉南方重点地区的393个社区实施.
主要成果:
- 在2022年,SCA将54个社区 (13.7%) 分类为高优先级,108个 (27.5%) 分类为中等优先级,231个 (58.8%) 分类为低优先级.
- 该SCA有效地解决了诸如偏远,广的领土和亚诺玛米人口的半游牧,跨境移动等挑战.
- 基于风险和需要的优先考虑增加了消除瘤瘤的可行性.
结论:
- 记分卡方法是规划,监测和最大限度地提高瘤病控制计划效率的宝贵策略.
- 实施SCA有助于在亚诺玛米重点地区最脆弱的社区进行有针对性的干预.
- 优先考虑高风险社区对于实现到2025年在美洲消除瘤病至关重要.
相关概念视频
01:26Methods Of Healthcare Delivery System
At the different levels of the healthcare system, we see varying methods of healthcare used. These methods include managed care systems, case management, and primary healthcare.
Managed Care System:
The managed care system is designed to control the cost while maintaining the quality of care. The patient's care from admission to discharge is planned by the primary care provider or the case manager, also known as the gatekeeper. In a managed care system, the number of care providers is limited...
Managed Care System:
The managed care system is designed to control the cost while maintaining the quality of care. The patient's care from admission to discharge is planned by the primary care provider or the case manager, also known as the gatekeeper. In a managed care system, the number of care providers is limited...
01:30Leishmaniasis
Leishmaniasis is a protozoal disease caused by species of the genus Leishmania and transmitted through the bite of infected female sandflies. The parasite exists in two principal morphological forms during its life cycle. A sandfly acquires intracellular amastigotes from an infected reservoir host, such as a dog. Within the sandfly, these forms differentiate into motile, flagellated promastigotes. During a subsequent blood meal, promastigotes are injected into the human host, where they...
01:29Malaria
Malaria pathogenesis in humans reflects a delicate interplay between parasite biology and host response. Clinical illness reflects a host’s immune response to the parasite’s asexual replication cycle, which is often asymptomatic in individuals with partial immunity. From the parasite's perspective, transmission between mosquito and human with minimal host pathology is evolutionarily advantageous. Among the six Plasmodium species infecting humans, P. falciparum and P. vivax dominate in global...
01:22American Trypanosomiasis
Chagas disease, or American trypanosomiasis, is a vector-borne parasitic infection caused by Trypanosoma cruzi, a flagellated protozoan (kinetoplastid) of the family Trypanosomatidae. The disease is endemic in Latin America, although cases are increasingly reported worldwide due to human migration. Transmission most commonly occurs when feces of infected triatomine bugs contaminate bite wounds or mucosal surfaces; additional routes include congenital, transfusional, transplant-related, and oral...
01:15Anthelminthic Agents
Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
01:21Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...